Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 131

1.

Low hepatitis B envelope antigen seroconversion rate in chronic hepatitis B patients on long-term entecavir 0.5 mg daily in routine clinical practice.

Liu A, Ha NB, Lin B, Yip B, Trinh HN, Nguyen HA, Nguyen KK, Ahmed A, Garcia G, Nguyen MH.

Eur J Gastroenterol Hepatol. 2013 Mar;25(3):338-43. doi: 10.1097/MEG.0b013e32835b3677.

PMID:
23169311
[PubMed - indexed for MEDLINE]
2.

Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.

Lok AS, Trinh H, Carosi G, Akarca US, Gadano A, Habersetzer F, Sievert W, Wong D, Lovegren M, Cohen D, Llamoso C.

Gastroenterology. 2012 Sep;143(3):619-28.e1. doi: 10.1053/j.gastro.2012.05.037. Epub 2012 May 27.

PMID:
22643350
[PubMed - indexed for MEDLINE]
3.

Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: a meta-analysis.

Su QM, Ye XG.

World J Gastroenterol. 2012 Nov 21;18(43):6290-301. doi: 10.3748/wjg.v18.i43.6290. Review.

PMID:
23180951
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naïve chronic hepatitis B patients in real life.

Luo J, Li X, Wu Y, Lin G, Pang Y, Zhang X, Ao Y, Du Z, Zhao Z, Chong Y.

Int J Med Sci. 2013;10(4):427-33. doi: 10.7150/ijms.5472. Epub 2013 Mar 1.

PMID:
23471472
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.

Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI.

J Gastroenterol Hepatol. 2010 Aug;25(8):1374-80. doi: 10.1111/j.1440-1746.2010.06381.x.

PMID:
20659226
[PubMed - indexed for MEDLINE]
6.

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, Poordad F, Halota W, Horsmans Y, Tsai N, Zhang H, Tenney DJ, Tamez R, Iloeje U.

Hepatology. 2010 Feb;51(2):422-30. doi: 10.1002/hep.23327.

PMID:
20049753
[PubMed - indexed for MEDLINE]
7.

High rates of viral suppression after long-term entecavir treatment of Asian patients with hepatitis B e antigen-positive chronic hepatitis B.

Pan CQ, Tong M, Kowdley KV, Hu KQ, Chang TT, Lai CL, Yoon SK, Lee SS, Cohen D, Tang H, Tsai N.

Clin Gastroenterol Hepatol. 2012 Sep;10(9):1047-1050.e1. doi: 10.1016/j.cgh.2012.03.016. Epub 2012 Apr 1.

PMID:
22475742
[PubMed - indexed for MEDLINE]
8.

Efficacy and safety of entecavir in clinical practice in treatment-naive Caucasian chronic hepatitis B patients.

Buti M, Morillas RM, Prieto M, Diago M, Pérez J, Solà R, Bonet L, Palau A, Testillano M, García-Samaniego J, Rodríguez M; ORIENTE Study Group.

Eur J Gastroenterol Hepatol. 2012 May;24(5):535-42. doi: 10.1097/MEG.0b013e3283511287. Erratum in: Eur J Gastroenterol Hepatol. 2012 Aug;24(8):999.

PMID:
22382708
[PubMed - indexed for MEDLINE]
9.

Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B.

Song MJ, Song do S, Kim HY, Yoo SH, Bae SH, Choi JY, Yoon SK, Paik YH, Lee JS, Lee HW, Kim HJ.

World J Gastroenterol. 2012 Nov 21;18(43):6277-83. doi: 10.3748/wjg.v18.i43.6277.

PMID:
23180949
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice.

Lin B, Ha NB, Liu A, Trinh HN, Nguyen HA, Nguyen KK, Ahmed A, Keeffe EB, Garcia RT, Garcia G, Nguyen MH.

J Gastroenterol Hepatol. 2013 May;28(5):855-60. doi: 10.1111/jgh.12108.

PMID:
23278507
[PubMed - indexed for MEDLINE]
11.

Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.

Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL.

Am J Gastroenterol. 2011 Jul;106(7):1264-71. doi: 10.1038/ajg.2011.45. Epub 2011 Mar 1.

PMID:
21364549
[PubMed - indexed for MEDLINE]
12.

A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice.

Tsai MC, Lee CM, Chiu KW, Hung CH, Tung WC, Chen CH, Tseng PL, Chang KC, Wang JH, Lu SN, Yen YH, Hu TH.

J Antimicrob Chemother. 2012 Mar;67(3):696-9. doi: 10.1093/jac/dkr495. Epub 2011 Dec 15.

PMID:
22174039
[PubMed - indexed for MEDLINE]
Free Article
13.

Virological, serological and biochemical outcomes through 3 years of entecavir treatment in nucleoside-naive Chinese chronic hepatitis B patients.

Yao GB, Ren H, Xu DZ, Zhou XQ, Jia JD, Wang YM, Chen CW.

J Viral Hepat. 2010 Mar;17 Suppl 1:51-8.

PMID:
20586934
[PubMed - indexed for MEDLINE]
14.

Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.

Ono A, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitou S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Kumada H.

J Hepatol. 2012 Sep;57(3):508-14. doi: 10.1016/j.jhep.2012.04.037. Epub 2012 May 30.

PMID:
22659518
[PubMed - indexed for MEDLINE]
15.

Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir.

Wang CC, Tseng KC, Peng CY, Hsieh TY, Lin CL, Su TH, Tseng TC, Hsu CS, Lin HH, Kao JH.

J Gastroenterol Hepatol. 2013 Jan;28(1):46-50. doi: 10.1111/j.1440-1746.2012.07269.x.

PMID:
22989322
[PubMed - indexed for MEDLINE]
16.

Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection.

Yokosuka O, Takaguchi K, Fujioka S, Shindo M, Chayama K, Kobashi H, Hayashi N, Sato C, Kiyosawa K, Tanikawa K, Ishikawa H, Masaki N, Seriu T, Omata M.

J Hepatol. 2010 Jun;52(6):791-9. doi: 10.1016/j.jhep.2009.12.036. Epub 2010 Mar 24.

PMID:
20409606
[PubMed - indexed for MEDLINE]
17.

Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment.

Fung J, Lai CL, Young J, Wong DK, Yuen J, Seto WK, Yuen MF.

Am J Gastroenterol. 2011 Oct;106(10):1766-73. doi: 10.1038/ajg.2011.253. Epub 2011 Aug 9.

PMID:
21826112
[PubMed - indexed for MEDLINE]
18.

Efficacy and tolerability of pegylated interferon-α-2a in chronic hepatitis B: a multicenter clinical experience.

Ratnam D, Dev A, Nguyen T, Sundararajan V, Harley H, Cheng W, Lee A, Rusli F, Chen R, Bell S, Pianko S, Sievert W.

J Gastroenterol Hepatol. 2012 Sep;27(9):1447-53. doi: 10.1111/j.1440-1746.2011.07051.x.

PMID:
22168789
[PubMed - indexed for MEDLINE]
19.

Correlation of serum hepatitis B surface antigen level with response to entecavir in naïve patients with chronic hepatitis B.

Lee MH, Lee da M, Kim SS, Cheong JY, Cho SW.

J Med Virol. 2011 Jul;83(7):1178-86. doi: 10.1002/jmv.22089.

PMID:
21567421
[PubMed - indexed for MEDLINE]
20.

Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B.

Sonneveld MJ, Wong VW, Woltman AM, Wong GL, Cakaloglu Y, Zeuzem S, Buster EH, Uitterlinden AG, Hansen BE, Chan HL, Janssen HL.

Gastroenterology. 2012 Mar;142(3):513-520.e1. doi: 10.1053/j.gastro.2011.11.025. Epub 2011 Nov 19.

PMID:
22108195
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk